Merck Reports KEYTRUDA Received 5 New Approvals In Japan, Including Advanced Non-Small Cell Lung Cancer, As Adjuvant Therapy for Melanoma, In Advanced Microsatellite Instability-High Tumors
Benzinga Newsdesk